首页> 美国卫生研究院文献>Journal of Oncology Practice >Coverage Policy Development for Personalized Medicine: Private Payer Perspectives on Developing Policy for the 21-Gene Assay

【2h】

Coverage Policy Development for Personalized Medicine: Private Payer Perspectives on Developing Policy for the 21-Gene Assay

机译：个性化医疗保险政策的制定：私人付款人对制定21基因检测政策的看法

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose:Personalized medicine is changing oncology practice and challenging decision making. A key challenge is the limited clinical evidence for many personalized medicine technologies. We describe the strategies private payers employed to develop coverage policy for personalized medicine using the example of the 21-gene assay in breast cancer.

机译：目的：个性化医学正在改变肿瘤学实践并挑战决策。一个关键的挑战是许多个性化医学技术的临床证据有限。我们以乳腺癌的21基因检测为例，介绍了私人付款人用于制定个性化医疗保险政策的策略。

著录项

期刊名称 Journal of Oncology Practice
作者
Julia R. Trosman; Stephanie L. Van Bebber; Kathryn A. Phillips;
展开▼
作者单位

展开▼
年(卷),期 2010(6),5
年度 2010
页码 238–242
总页数 5
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Coverage Policy Development for Personalized Medicine: Private Payer Perspectives on Developing Policy for the 21-Gene Assay [J] . Julia R. Trosman, Stephanie L. Van Bebber, Kathryn A. Phillips Journal of Oncology Practice . 2010,第5期

机译：个性化医疗保险政策的制定：私人付款人对制定21基因检测政策的看法
2. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: A report of the ISPOR personalized medicine special interest group [J] . FaulknerE., AnnemansL., GarrisonL., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2012,第8期

机译：个性化药品付款人和制造商的观点在发展和报销方面的挑战以及对健康经济学和结果研究的影响：ISPOR个性化医学特别兴趣小组的报告
3. Health Technology Assessment and Private Payers' Coverage of Personalized Medicine [J] . Julia R. Trosman, Stephanie L. Van Bebber, Kathryn A. Phillips Journal of Oncology Practice . 2011,第3期

机译：卫生技术评估和私人付款人的个性化医疗保险
4. A Policy Tool on Developing a National Strategic Framework on Bridging Digital Divide: A Malaysian Public Policy Perspective [C] . Ramasamy Ramachandran 2nd international conference on theory and practice of electronic governance 2008 . 2008

机译：制定弥合数字鸿沟的国家战略框架的政策工具：马来西亚公共政策视角
5. Economic evaluation of 21-gene assay for early stage breast cancer patients from the perspective of the Chinese health care system. [D] . Zhou, Mi. 2012

机译：从中国卫生保健系统的角度对早期乳腺癌患者进行21基因检测的经济评价。
6. Private Payer Coverage Policies for Whole Exome Sequencing (WES) inPediatric Patients: Trends Over Time and Analysis of EvidenceCited [O] . Michael P. Douglas, Stephanie L. Parker, Julia R. Trosman, -1

机译：美国全外显子测序（WES）的私人付款人承保政策儿科患者：随时间变化的趋势和证据分析被引
7. Coverage Policy Development for Personalized Medicine: Private Payer Perspectives on Developing Policy for the 21-Gene Assay [O] . Trosman, Julia R., Van Bebber, Stephanie L., Phillips, Kathryn A. 2010

机译：个性化医疗保险政策的制定：私人付款人对制定21基因检测政策的看法

Coverage Policy Development for Personalized Medicine: Private Payer Perspectives on Developing Policy for the 21-Gene Assay

摘要

著录项

相似文献

相关主题

期刊订阅